Krka Logo

Krka

Develops and sells generic prescription, non-prescription, and animal health products globally.

KRKG | LJSE

Overview

Corporate Details

ISIN(s):
SI0031102120
LEI:
549300H9RLRTRTLRUZ73
Country:
Slovenia
Address:
Šmarješka cesta 006, 8501 Novo mesto
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Krka is a leading international generic pharmaceutical company focused on the development, production, marketing, and sale of human and animal health products. With over 70 years of experience, the company's core business is providing high-quality and innovative generic medicines. Its portfolio is composed of three main segments: prescription pharmaceuticals for treating common diseases, non-prescription products for minor illnesses and preventative care, and a range of animal health products. Krka's products are marketed globally, serving patients in more than 70 countries.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-08 08:30
Regulatory News Service
Conclusion regarding perindopril litigation
English 1.4 KB
2025-10-08 08:30
Regulatory News Service
Odločitev Komisije EU v zadevi perindopril
Slovene 1.4 KB
2025-09-29 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 142.3 KB
2025-09-29 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.2 KB
2025-09-29 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 137.5 KB
2025-09-29 08:30
Transaction in Own Shares
Pridobivanje lastnih delnic
Slovene 2.2 KB
2025-09-22 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 124.7 KB
2025-09-22 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.2 KB
2025-09-22 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 122.2 KB
2025-09-22 08:30
Transaction in Own Shares
Pridobivanje lastnih delnic
Slovene 2.2 KB
2025-09-19 08:30
Board/Management Information
Konstitutivna seja nadzornega sveta Krke, d. d., Novo mesto
Slovene 1.4 KB
2025-09-19 08:30
Board/Management Information
Constitutive session of the Supervisory Board of Krka, d. d., Novo mesto
English 1.4 KB
2025-09-15 08:30
Transaction in Own Shares
Detailed report on acquisition of treasury shares
English 133.3 KB
2025-09-15 08:30
Transaction in Own Shares
Acquisition of treasury shares
English 2.2 KB
2025-09-15 08:30
Transaction in Own Shares
Podrobno poročilo o nakupih lastnih delnic
English 130.6 KB

Automate Your Workflow. Get a real-time feed of all Krka filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Krka via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.